Xeris Biopharma Holdings (XERS) Interest Coverage Ratio (2020 - 2026)
Xeris Biopharma Holdings (XERS) posted Interest Coverage Ratio of 0.92 for Q1 2026, down 71.5% on a QoQ basis from 3.21 in Q4 2025, and up 356.18% year-over-year from 0.2 in Q1 2025.
Xeris Biopharma Holdings (XERS) Interest Coverage Ratio (2020 - 2026) Analysis & Trends
Xeris Biopharma Holdings' Interest Coverage Ratio history runs 7 years deep, the most recent figure standing at 0.92 for Q1 2026.
- Quarterly Interest Coverage Ratio rose 356.18% year-over-year to 0.92 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 4.15 (up 259.63% YoY) and the FY2025 annual result came in at 0.58, up 441.03% from the prior year.
- Interest Coverage Ratio was 0.92 for Q1 2026 at Xeris Biopharma Holdings, down from 3.21 in the prior quarter.
- Across five years, Interest Coverage Ratio topped out at 3.21 in Q4 2025 and bottomed at 3.47 in Q4 2022.
- A 5-year average of 0.72 and a median of 0.95 in 2024 frame the typical range for Interest Coverage Ratio.
- Annual changes were most pronounced in 2023 — Interest Coverage Ratio plunged 660.24% — and 2025, when it soared 1052.66%.
- Xeris Biopharma Holdings' Interest Coverage Ratio stood at 3.47 in 2022, then soared by 65.0% to 1.22 in 2023, then jumped by 122.93% to 0.28 in 2024, then surged by 1052.66% to 3.21 in 2025, then plunged by 71.5% to 0.92 in 2026.
- Business Quant data shows XERS's Interest Coverage Ratio at 0.92 in Q1 2026, 3.21 in Q4 2025, and 0.78 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | - |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 13.44 |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -2.81 |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 0.18 |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | -0.07 |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 0.33 |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 5.11 |
| 10 | Xeris Biopharma Holdings | 1.43 Bn | 1.32 Bn | 72.55 Mn | 0.92 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 0.92 |
| Dec 31, 2025 | 3.21 |
| Sep 30, 2025 | 0.78 |
| Jun 30, 2025 | 0.15 |
| Mar 31, 2025 | -0.36 |
| Dec 31, 2024 | 0.28 |
| Sep 30, 2024 | -1.49 |
| Jun 30, 2024 | -0.95 |
| Mar 31, 2024 | -1.65 |
| Dec 31, 2023 | -1.22 |
| Sep 30, 2023 | -0.57 |
| Jun 30, 2023 | -1.85 |
| Mar 31, 2023 | -1.35 |
| Dec 31, 2022 | -3.47 |
| Sep 30, 2022 | -1.82 |
| Jun 30, 2022 | -0.24 |
| Mar 31, 2022 | -2.68 |
| Dec 31, 2021 | -26.58 |
| Sep 30, 2021 | -13.53 |
| Jun 30, 2021 | -14.33 |